Purpose The findings from the observational studies comparing the effectiveness and safety
of non–vitamin K antagonist oral anticoagulants (NOACs) versus vitamin K antagonists …

Background & Aims There is controversy over whether use of non-vitamin K antagonist oral
anticoagulants (NOACs) associates with increased risk of major gastrointestinal bleeding …

Background The introduction of non–vitamin K antagonist oral anticoagulants has been a
major advance for stroke prevention in atrial fibrillation; however, outcomes achieved in …

Background Patients with warfarin have a potential risk of warfarin-related nephropathy,
which could result in the discontinuation of anticoagulation therapy. The question of whether …

Atrial fibrillation (AF) and chronic kidney disease (CKD) are strictly related; several
independent risk factors of AF are often frequent in CKD patients. AF prevalence is very …

The aim of our article is to provide a concise review for clinicians entailing the main studies
that evaluated the efficacy and safety of target-specific oral anticoagulants (TSOAs) for …

Introduction Randomized clinical trials (RCTs) and real-world data (RWD) in patients with
atrial fibrillation have shown that—compared to vitamin K antagonists (VKAs)—non-VKA oral …

Objective: To conduct a systematic review of real-world (RWD) studies comparing the risk of
major bleeding (MB) among patients with non-valvular atrial fibrillation (NVAF) on direct oral …

Background The role of left atrial appendage occlusion (LAAO) for atrial fibrillation patients
that during oral anticoagulant therapy (OAC) suffer from ischemic events or present LAA …

Introduction: Several comparative real-world effectiveness studies on direct oral
anticoagulants (DOACs) have been conducted, but an overview of the available evidence …